Brief: Vivani Medical Announces Rapid Advancement Of NPM-139
05/08/2025 14:25
Aug 5 (Reuters) - Vivani Medical Inc VANI.O: VIVANI MEDICAL ANNOUNCES RAPID ADVANCEMENT OF NPM-139, A NOVEL SEMAGLUTIDE IMPLANT, FOLLOWING POSITIVE WEIGHT LOSS DATA FROM AN ONGOING PRECLINICAL STUDY OF NPM-139 AND PROMISING RESULTS FROM THE LIBERATE-1 PHASE 1 CLINICAL STUDY OF NPM-115 VIVANI MEDICAL INC - PRIORITIZES ADVANCEMENT OF NPM-139, WITH CLINICAL DEVELOPMENT EXPECTED TO BEGIN IN 2026 VIVANI MEDICAL- NEW NPM-139 PRECLINICAL FEASIBILITY DATA SHOWED ABOUT 20% WEIGHT LOSS MAINTAINED LONGER THAN 6 MONTHS WITH A SINGLE IMPLANT Source text: ID:nGNX1V4J29 Further company coverage: VANI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivani Medical
See all newsVivani Medical Q2 net loss narrows as expenses fall
Vivani Medical Inc reports results for the quarter ended June 30 - Earnings Summary
Vivani Medical Inc expected to post a loss of 8 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia